Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Risankizuma, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
This sheds light on the importance of following specific precautions during the induction of anesthesia for patients who are peri-procedurally taking semaglutide or other GLP-1 RAs to prevent pulmonary aspiration of gastric contents [24]
Effect of linagliptin vs placebo on major cardiovascular events in adults with Type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial
Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi
US$ 23.98
US$ 21.37
US$ 23.97
US$ 20.18
